Llusern Scientific develops the Lodestar DX, a rapid point-of-care molecular diagnostic platform that utilizes nucleic acid amplification to detect six pathogens responsible for 85% of urinary tract infections within 35 minutes. This technology provides healthcare providers with timely and accurate results, enabling informed treatment decisions and reducing unnecessary antibiotic prescriptions.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional laboratory culture methods for diagnosing urinary tract infections (UTIs) can take 24 hours or longer, delaying treatment and potentially leading to unnecessary antibiotic prescriptions. Dipstick tests offer a faster alternative but lack the sensitivity and specificity to accurately identify the causative bacteria. This can result in ineffective treatment and contribute to antibiotic resistance.
Solution
Llusern Scientific's Lodestar DX is a rapid, point-of-care molecular diagnostic platform that enables healthcare providers to quickly and accurately diagnose UTIs. The system utilizes nucleic acid amplification to detect six common UTI-causing pathogens directly from urine samples in approximately 35 minutes. By providing timely and reliable results, Lodestar DX empowers clinicians to make informed treatment decisions, prescribe targeted therapies, and reduce the overuse of broad-spectrum antibiotics. The platform eliminates the need for complex DNA/RNA extraction processes and highly trained personnel, making it suitable for use in a variety of clinical settings.
Target Audience
The primary target audience includes healthcare providers such as general practitioners, urologists, and veterinarians who require rapid and accurate UTI diagnostics at the point of care.
Features
- Rapid molecular testing platform providing results in 35 minutes
- Detects six pathogens responsible for approximately 85% of all UTIs: *Escherichia coli*, *Enterococcus spp*, *Staphylococcus spp.*, *Proteus mirabilis*, *Pseudomonas aeruginosa*, and *Klebsiella pneumoniae*
- Utilizes nucleic acid amplification for high accuracy and sensitivity
- Point-of-care testing eliminates the need for off-site laboratory analysis
- Affordable system that does not require expensive laboratory equipment or complex extraction processes
- UK CA marked and registered with the European Patent Office and the US Patent and Trademark Office
- Suitable for both human and veterinary applications